Nattokinase Encapsulated Nanomedicine for Targeted Thrombolysis: Development, Improved <i>in Vivo</i> Thrombolytic Effects, and Ultrasound/Photoacoustic Imaging

Priya, Vishnu; Samridhi,; Singh, Nitesh; Dash, Debabrata; Muthu, Madaswamy S.

doi:10.1021/acs.molpharmaceut.3c00830

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Preprint1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 63 publications

(116 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Edoxaban enfolded beta-1,4-poly- d -glucosamine nanoparticles for targeting eponym Stuart–Prower factor for treatment of venous thrombosis

Pazhani,

Dharmian,

Arumugam

et al. 2024

Journal of Drug Targeting

View full text Add to dashboard Cite

Edoxaban enfolded beta-1,4-poly- d -glucosamine nanoparticles for targeting eponym Stuart–Prower factor for treatment of venous thrombosis

Pazhani,

Dharmian,

Arumugam

et al. 2024

Journal of Drug Targeting

View full text Add to dashboard Cite

Automated microscopic measurement of fibrinaloid microclots and their degradation by nattokinase, the main natto protease

Grixti,

Theron,

Salcedo-Sora

et al. 2024

Preprint

View full text Add to dashboard Cite

Nattokinase, from the Japanese fermented food natto, is a protease with fibrinolytic activity that can thus degrade conventional blood clots. In some cases, however, including in Long COVID, fibrinogen can polymerise into an anomalous amyloid form to create clots that are resistant to normal fibrinolysis and that we refer to as fibrinaloid microclots. These can be detected with the fluorogenic stain thioflavin T. We describe an automated microscopic technique for the quantification of fibrinaloid microclot formation, which also allows the kinetics of their formation and aggregation to be recorded. We also here show that recombinant nattokinase is effective at degrading the fibrinaloid microclotsin vitro. This adds to the otherwise largely anecdotal evidence, that we review, that nattokinase might be anticipated to have value as part of therapeutic treatments for individuals with Long COVID and related disorders that involve fibrinaloid microclots.

show abstract

Nattokinase Encapsulated Nanomedicine for Targeted Thrombolysis: Development, Improved in Vivo Thrombolytic Effects, and Ultrasound/Photoacoustic Imaging

Cited by 2 publications

References 63 publications

Edoxaban enfolded beta-1,4-poly- d -glucosamine nanoparticles for targeting eponym Stuart–Prower factor for treatment of venous thrombosis

Edoxaban enfolded beta-1,4-poly- d -glucosamine nanoparticles for targeting eponym Stuart–Prower factor for treatment of venous thrombosis

Automated microscopic measurement of fibrinaloid microclots and their degradation by nattokinase, the main natto protease

Contact Info

Product

Resources

About